A Sl-year old male who had undergone a radical nephrectomy for T2NoMo Fuhrman grade III tumour 5 years back developed persistent loin pain. Clinically he had a palpable right hypochondriac mass. Imaging revealed a tumour over the previous surgical scar, renal fossa with inferior vena cava obstruction with no other metastatic disease. He underwent excision of the local recurrence, cavotomy, thrombectomy with caval resection since the tumour was adherent to the IVC. Histology confirmed it as a recurrence of renal cell carcinoma and was followed by targeted therapy.
We report an unusual case of late presentation of surgical site and renal fossa recurrence with invasion to the inferior vena cava (IVC) in a patient who underwent radical nephrectomy for a renal cell carcinoma (RCC). A review ofthe literature showed no previous published 
Discussion
Tumour recurrence of RCC reported varies from 10-37% where metastatic recurrence predominates with lung (63%), bone (27%), brain (20%), liver (16%), retroperitoneal lymph nodes (10%) far being the common sites (1) . Local recurrence of RCC after radical nephrectomy remains an uncommon event. Published series report that between 2% and 5% of patients with RCC will develop a local recurrence after radical nephrectomy (2). However, majority of patients with local recurrence also has systemic disease at diagnosis; only 10-17% of patients have true isolated local recurrences.
Time to tumour recurrence generally occurs within the first 2 years with generally 83% affected (3). Though late metastatic recurrence is reported even after 20 years, literature on late local recurrence is scarce (4). The mean time of tumor recurrence usually is 17 months (range, 3-50 months). Not all patients with locally recurrent disease will be symptomatic at presentation. The presence of symptoms leading to the discovery of a recurrence varies widely from 7% to 73%. The majority of the published series shows that patients who died had a mean time to recurrence of 16 months, compared with 79 months for patients who survived. These findings reinforce the well-known heterogeneity of the characteristics of RCC and its clinical behaviour (6).
Since RCC has poor response to adjuvant treatments, surgery is the best choice in a case of local recurrence or isolated metastatic recurrence in the absence of metastatic disease in other places. An aggressive surgical resection can provide up to 30% 5-year disease-free survival. However, complete surgical resection with negative surgical margins is crucial and en bloc resection of adjacent organs should be done to achieve this goal. Failing to do so will likely result in recurrent disease and decreased survival. It is not surprising, then, that most published series report complication rates ranging from 18% to 47% (7).
Surgery for IVC recurrence is rarity. If encountered the options available are tumor thrombus removal and primary cavotomy closure, IVC ligation and removal of tumour thrombus without vascular reconstruction and IVC wall excision and placement of a bovine pericardium or PTFE graft (8) . Although technically difficult, resection of IVC tumour and primary closure as in this case is an acceptable method of treatment.
Although many of the published reports support the potential benefit associated with an aggressive surgical approach, the role of systemic therapy or radiation therapy remains to be defined. So far, most authors report that disease control with both treatment modalities is far more less over surgery. Radiation therapy may be of value for palliation of symptomatic local recurrence for patients who are not surgical candidates.
Prognosis of these patients with recurrence has an inverse correlation between the number of risk factors which include time from diagnosis to start of systemic therapy <12 months, Karnofsky index <80%, serum corrected calcium >10 mg/dL, haemoglobin less than the age/sex-specific lower limit of normal and an LDH more than 1.5× the upper limit of normal. Patients were categorized into those with low risk (no risk factors), intermediate risk (1-2 risk factors present) and high risk (3-5 risk factors present) 2-year overall survival rates were 88%, 51% and 11%, respectively (5).
